VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
173.00
-2.93 (-1.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close175.93
Open174.38
Bid169.95 x 800
Ask176.17 x 800
Day's Range171.81 - 175.65
52 Week Range136.50 - 183.39
Volume717,045
Avg. Volume1,529,167
Market Cap44.212B
Beta1.86
PE Ratio (TTM)107.25
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters14 hours ago

    Vertex cystic fibrosis drug gets expanded approval for use in infants

    U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc's cystic fibrosis drugs to include patients aged between 12 months and 24 months. The expanded approval makes Kalydeco the first medicine to treat the underlying cause of the genetic disease in this age group among patients with specific mutations in the CF transmembrane regulator (CFTR) gene, Vertex said on Wednesday. The drug is currently approved in the United States to treat patients aged 2 and older whose CFTR gene has certain mutations.

  • Benzinga22 hours ago

    The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...

  • Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
    Zacks2 days ago

    Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit

    Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.

  • Benzinga3 days ago

    The Week Ahead: Nvidia, Retailer Earnings In Focus

    Below is a list of notable corporate events for the week beginning August 13. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on NTAP Monday ...

  • 7 Fast-Growing Stocks to Buy Today
    InvestorPlace3 days ago

    7 Fast-Growing Stocks to Buy Today

    If you haven’t noticed, there has been a lot of talk about something that we haven’t heard about for almost a decade — inflation.

  • Analyst Recommendations for Exelixis in August
    Market Realist7 days ago

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplinger7 days ago

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018

  • Is Crispr Therapeutics Stock Grossly Overvalued?
    Motley Fool7 days ago

    Is Crispr Therapeutics Stock Grossly Overvalued?

    Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?

  • Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2
    Zacks7 days ago

    Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2

    Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.

  • Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
    Zacks7 days ago

    Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

    Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.

  • 3 Top Biotech Stocks to Buy in August
    Motley Fool8 days ago

    3 Top Biotech Stocks to Buy in August

    It could be the perfect time to add shares in these biotech companies to portfolios ahead of key catalysts.

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX

  • Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
    Zacks8 days ago

    Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

    The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

  • Barrons.com9 days ago

    8 Biotechs Still Worth Buying After a Sector Surge

    Stifel updated its outlook on the biotech sector, and sees reason to be bullish on several big names. While biotech has had its ups and downs, in general this has been a good year to be in the sector: The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 10.7% and 12.8%, respectively, since the start of 2018, above the broader market and even the gain seen by the increasing popular health-care sector itself, as the Health Care Select Sector SPDR ETF (XLV) is up 8.8% since the start of the year.  While smaller biotechs have benefited more from the moves, there are still some bigger companies that warrant attention, argues Stifel's Paul Matteis. Stifel transferred and initiated coverage on a number of biotech stocks, today, with Buy ratings on Vertex Pharmaceuticals  (VRTX), BioMarin Pharmaceuticals (BMRN), Biogen (BIIB), Alnylam Pharmaceuticals (ANLY), Sage Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Wave Life Sciences (WVE), and Alder BioPharmaceuticals (ALDR).

  • Analysts Are Bullish on Sarepta Therapeutics
    Market Realist9 days ago

    Analysts Are Bullish on Sarepta Therapeutics

    Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.

  • This stock sector most often beats analysts’ estimates
    MarketWatch10 days ago

    This stock sector most often beats analysts’ estimates

    Sixty-one of 63 health-care companies have exceeded analysts’ estimates when they reported their most recent results.

  • Benzinga10 days ago

    The Week Ahead: Earnings From Disney, Roku And Snap, Rite Aid Votes On Albertsons Deal

    Below is a list of notable corporate events for the week beginning August 6. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMZN Monday ...

  • Why Boston and central Texas have so many of the best-paying companies in the U.S. Here's where other cities are missing out.
    American City Business Journals13 days ago

    Why Boston and central Texas have so many of the best-paying companies in the U.S. Here's where other cities are missing out.

    Driving the trend are highly specialized workers who, through years of schooling and research, fill lucrative roles demanding unusual or, in many cases, unparalleled skill sets.

  • Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track
    Zacks14 days ago

    Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track

    Ophthotech reports narrower-than-expected loss in the second quarter.

  • Reuters14 days ago

    Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study

    Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function. There are few treatment options for the 70,000 cystic fibrosis patients worldwide, who rarely live beyond 40 and possess a defective gene that leads to the build-up of thick mucus which clogs the lungs and other organs, often triggering inflammation. The company is considering private financing, a public offering and possible financial support from the Cystic Fibrosis Foundation ahead of a late-stage study set for the second half of 2019, Chief Executive Officer Greg Duncan told Reuters.

  • Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit
    Zacks15 days ago

    Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit

    Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

  • 9 Near-Monopolies That Are Legal in America
    Motley Fool16 days ago

    9 Near-Monopolies That Are Legal in America

    Does the pricing power harnessed by these companies make them good investments?

  • Thomson Reuters StreetEvents16 days ago

    Edited Transcript of VRTX earnings conference call or presentation 25-Jul-18 8:30pm GMT

    Q2 2018 Vertex Pharmaceuticals Inc Earnings Call

  • Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue
    Motley Fool17 days ago

    Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue

    The biotech benefits from economies of scale.

  • Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem?
    Investor's Business Daily17 days ago

    Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem?

    Gilead Sciences could swipe its next chief executive from privately held Dermavant or seek a major merger with Vertex Pharmaceuticals or Dow Jones' Pfizer, investors suggested.